Coeptis Therapeutics is a biopharmaceutical
company developing innovative cell therapy
platforms for patients with cancer.
OUR Mission:
TO IMPROVE outcomes for patients with cancer
Involves innovative cell therapy platforms
Learn More
Coeptis Therapeutics is a biopharmaceutical company developing innovative cell therapy platforms for patients with cancer
Learn More
For more information regarding Press Releases, stock information
Learn More
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.
Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.
To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing tumor killing and immune surveillance.
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.
Coeptis Therapeutics Holdings, Inc. conducts its commercial operations primarily through its wholly-owned subsidiary Coeptis Pharmaceuticals, Inc.
Read More
Read More
Read More
To get the latest News articles and Press Releases, click on the learn more link below
